Tasha Shamlin, MD
Pediatrics · Baton Rouge, LANPI 1568468296
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 239 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,898 and has fallen 75.5% since, to $465 in 2025. Among pediatrics clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$595
- Novo Nordisk$529
- AstraZeneca$447
- Boehringer Ingelheim$375
- Merck$259
- Sanofi-aventis U.S. LLC$255
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,896100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 44 | $595 |
| Novo Nordisk | 37 | $529 |
| AstraZeneca | 22 | $447 |
| Boehringer Ingelheim | 23 | $375 |
| Merck | 20 | $259 |
| Sanofi-aventis U.S. LLC | 16 | $255 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $195 |
| Si-bone, Inc. | 1 | $149 |
| AbbVie(2 entities) | 6 | $118 |
| Abbott | 3 | $102 |
| Kowa Pharmaceuticals America, Inc. | 7 | $100 |
| Amgen | 5 | $72 |
| Genentech USA, Inc. | 3 | $64 |
| Johnson & Johnson | 5 | $60 |
| Medtronic | 3 | $51 |
| Bayer | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Pfizer | 3 | $40 |
| GSK | 2 | $35 |
| Novartis | 2 | $35 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| Insulet Corporation | 2 | $27 |
| Corcept Therapeutics | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Merz North America, Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Cranial Technologies, Inc | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Neos Therapeutics, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iFuse Implant$149
- FARXIGA$125
How this compares
$3,911 in reported general payments places this provider in the 95th percentile of 913 pediatrics providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 164 | $218,540 |
| OzempicSemaglutide | 143 | $185,033 |
| JanuviaSitagliptin Phosphate | 117 | $121,655 |
| TrulicityDulaglutide | 51 | $79,862 |
| JardianceEmpagliflozin | 28 | $34,088 |
| FarxigaDapagliflozin Propanediol | 43 | $29,474 |
| RybelsusSemaglutide | 27 | $28,507 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $14,442 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $13,139 |
| LinzessLinaclotide | 12 | $8,302 |
| Atorvastatin Calcium | 309 | $5,714 |
| Clonidine | 17 | $5,578 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $3,465 |
| Rosuvastatin Calcium | 172 | $3,080 |
| Metoprolol Succinate | 170 | $2,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $595 | $298,402215 claims |
| Novo NordiskOzempic, Rybelsus | $529 | $213,541170 claims |
| MerckJanuvia | $259 | $121,655117 claims |
| Boehringer IngelheimJardiance | $375 | $34,08828 claims |
| AstraZenecaFarxiga | $447 | $29,47443 claims |
| AbbVieLinzess, Synthroid | $118 | $9,08730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 913 pediatrics providers in Louisiana.
Other pediatrics in Baton Rouge
- Caroline KlineBaton Rouge$8K
- Aimee CailletBaton Rouge$5K
- Darryl SanchesBaton Rouge$4K
- Lacey St AmantBaton Rouge$4K
- Briana MayoBaton Rouge$4K
- Lacey ClarkBaton Rouge$3K
- Reuben BattleyBaton Rouge$2K
- Corey HebertGretna$1.3M
- Katie QueenBogalusa$61K
- Elizabeth WhiteCovington$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.